alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

30,980 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 101–125 of 126 studies in Mild cognitive impairment · tagged Brain Scans (page 5 of 6) · 30,980 in the whole library · How the 0–100 score works

Download bibliography of these 126 studies, in this order: BibTeX (.bib) · RIS (.ris)

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Other subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Institutions

From OpenAlex; 16,452 studies have no institution on record and are not counted here.

What “Mild cognitive impairment” covers

Mild cognitive impairment — The stage between normal ageing and dementia: who progresses, who doesn't, and what predicts it.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

The role of quantitative EEG biomarkers in Alzheimer’s disease and mild cognitive impairment: applications and insights

✓ Peer-reviewed alzhub usefulness score 45 out of 100. Frontiers in Aging Neuroscience 2025-04-23

Alzheimer's disease (AD) is characterized by the pathological accumulation of amyloid plaques and hyperphosphorylated tau proteins, leading to disruptions in synaptic transmission and neural circuit alterations. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Characterizing bidirectional transitions in mild cognitive impairment and post‐reversion based on longitudinal neuroimaging and cognitive assessments

✓ Peer-reviewed alzhub usefulness score 44 out of 100. Alzheimer s & Dementia 2025-05-01

The probability of reversion increased from 2% at baseline to a maximum of 8% by year 10 before gradual decline thereafter. 5 key findings →

Design: retrospective cohort Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Sex-specific effects of apolipoprotein E ε4 genotype on longitudinal hippocampal atrophy in amnestic mild cognitive impairment over a 2-year evaluation period

✓ Peer-reviewed alzhub usefulness score 44 out of 100. Journal of Alzheimer s Disease 2025-02-01

We identified that the APOE4 genotype affected ΔHV in females. 5 key findings →

Design: longitudinal study Participants: 73 Evidence: moderate

Full summary, score breakdown and related studies → Original source Full text may need a subscription

The Utility of Cerebral Blood Flow as a Biomarker of Preclinical Alzheimer's Disease

✓ Peer-reviewed alzhub usefulness score 43 out of 100. Cellular and molecular neurobiology 2016-02-22

There is accumulating evidence suggesting that changes in brain perfusion are present long before the clinical symptoms of Alzheimer's disease (AD), perhaps even before amyloid-β accumulation or brain atrophy. 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Mild cognitive impairment

✓ Peer-reviewed alzhub usefulness score 43 out of 100. The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry 2005-08-01

Mild cognitive impairment (MCI) describes a state of cognitive functioning that is below defined norms, yet falls short of dementia in severity. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

A radiomics model predicts progression from mild cognitive impairment to alzheimer’s disease using structural MRI

✓ Peer-reviewed alzhub usefulness score 43 out of 100. Scientific Reports 2025-10-13

The aim of this study is to build and validate a model based on structural magnetic resonance imaging (sMRI) to predict the progression of mild cognitive impairment (MCI) to Alzheimer's disease (AD). 3 key findings →

Participants: 240 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

The Differentiation of Amnestic Type MCI from the Non-Amnestic Types by Structural MRI

✓ Peer-reviewed alzhub usefulness score 42 out of 100. Frontiers in aging neuroscience 2016-03-30

The amnestic mild cognitive impairment/non-amnestic mild cognitive impairment separation is not only theoretical but backed by structural imaging methods and neuropsychological tests. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Statistical Method for Identification of Alzheimer's Disease in Mild Cognitive Impairment with Multimodal Predictive Markers

✓ Peer-reviewed alzhub usefulness score 39 out of 100. Basic and Clinical Neuroscience Journal 2025-03-01

Our findings showed the strong predictive potential of PET, particularly florbetaben (FBB), which achieved an AUC of 0.84. 5 key findings →

Participants: 487 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Moderating role of triglycerides in the relationship between amyloid-β, hippocampal atrophy, and cognitive decline in mild cognitive impairment and early Alzheimer’s disease

✓ Peer-reviewed alzhub usefulness score 39 out of 100. Frontiers in Aging Neuroscience 2025-08-22

These findings highlight hippocampal atrophy as a key pathway linking Aβ burden to cognitive impairment. 4 key findings →

Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Dynamic changes in PET amyloid and FDG imaging at different stages of Alzheimer's disease

✓ Peer-reviewed alzhub usefulness score 38 out of 100. Neurobiology of aging 2010-08-04

In this study 5 patients with mild cognitive impairment (MCI) and 9 Alzheimer's disease (AD) patients underwent respectively 3- and 5-year follow-up positron emission tomography (PET) studies with N-methyl [(11)C] 2-(4-methylaminophenyl)-6-hydroxy-benzothiazole ((11)C-PIB) and (18)F-fluorodeoxyglucose ((18)F-FDG) to understand the time courses in AD disease processes. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source

Multimodal magnetic resonance imaging analysis of early mild cognitive impairment

✓ Peer-reviewed alzhub usefulness score 38 out of 100. Journal of Alzheimer s Disease 2025-03-03

BackgroundEarly mild cognitive impairment (EMCI) represents a prodromal stage of dementia, and early detection is crucial for delaying dementia progression. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Individualized prediction of transition from subjective cognitive decline to mild cognitive impairment based on multimodal MRI: a 10-year follow-up study

✓ Peer-reviewed alzhub usefulness score 38 out of 100. The Journal of Prevention of Alzheimer s Disease 2026-01-01

The model incorporating age, brain volume, functional, and radiomics features demonstrated the highest predictive performance for SCD progression in training (C-index: 0.962; 95 % CI: 0.95-0.98) and testing (C-index: 0.911; 95 % CI: 0.861-0.968) sets. 5 key findings →

Participants: 89 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

The Role of Magnetic Resonance Spectroscopy ( MRS ), Diffusion‐Tensor‐Imaging ( DTI ) and Structural MRI in the Alzheimer's Disease and Mild Cognitive Impairment Diagnosis: A Review

✓ Peer-reviewed alzhub usefulness score 37 out of 100. Journal of Magnetic Resonance Imaging 2026-03-19

Alzheimer's disease (AD) is one of the most common neurological disorders affecting older adults, with approximately 7.2 million cases only in the United States. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

High-resolution structural and functional MRI of hippocampal CA3 and dentate gyrus in patients with amnestic Mild Cognitive Impairment

✓ Peer-reviewed alzhub usefulness score 36 out of 100. NeuroImage 2010-03-23

Functional magnetic resonance imaging (fMRI) studies have observed hyperactivity in the hippocampal region in individuals with Mild Cognitive Impairment (MCI). 3 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source

Altered Default Mode Network Connectivity in Mild Cognitive Impairment: Insights from Resting-State fMRI Studies

✓ Peer-reviewed alzhub usefulness score 33 out of 100. Current Alzheimer Research 2025-02-01

Mild Cognitive Impairment (MCI) is marked by a measurable decline in cognitive function that exceeds typical age-related changes but does not yet qualify as dementia. 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Neuro-JEPA: Building and Evaluating Health-System Scale Neuroimaging Foundation Models with Mixture of Experts

⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. Research Square 2026-10-15

Magnetic resonance imaging (MRI) of the brain routinely combines complementary contrasts—including T1-weighted (T1w), T2-weighted (T2w) and FLAIR sequences—to capture anatomy and pathology. 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 30,980 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 30,980 records, built mostly from automated pulls of Europe PMC (65.2% of the library) and OpenAlex (16.4%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,042 records (3.4% of the library) are not peer-reviewed — 967 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed    Where this research is being discussed: events